Actuate TherapeuticsACTU -14.29%14 Quick Ratio is 1.80 as of Mar. 2026, which is 71% above its 10-year median of 1.05. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 1,416 Biotechnology companies, Actuate Therapeutics ranks worse than 68.22% on this metric.
Actuate Therapeutics has a quick ratio of 1.80. It generally indicates good short-term financial strength.
The historical rank and industry rank for Actuate Therapeutics's Quick Ratio or its related term are showing as below:
ACTU'
s Quick Ratio Range Over the Past 10 Years
Min: 0.03 Med: 1.05 Max: 4.71
Current: 1.8
During the past 4 years, Actuate Therapeutics's highest Quick Ratio was 4.71. The lowest was 0.03. And the median was 1.05.
ACTU's Quick Ratio is ranked worse than 68.22% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs ACTU: 1.80
Actuate Therapeutics (NAS:ACTU) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Actuate Therapeutics Quick Ratio Related Terms
Actuate Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Actuate Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Actuate Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actuate Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Actuate Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Actuate Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actuate Therapeutics (ACTU) has a Quick Ratio of 1.80 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Actuate Therapeutics and its competitors. This is 71% above median its historical median of 1.05. Over the past decade, Actuate Therapeutics' Quick Ratio has ranged from 0.03 to 4.71. According to the industry distribution chart, Actuate Therapeutics ranks #966 out of 1416 companies in the Biotechnology industry, placing it in the top 68.2%.
Is Actuate Therapeutics' Quick Ratio too high?
Actuate Therapeutics' current Quick Ratio of 1.80 is 71% above median its 10-year median of 1.05. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 4.71. The Biotechnology industry median Quick Ratio is 3.60. Actuate Therapeutics' value of 1.80 is 50% below this industry median. Based on the distribution chart, Actuate Therapeutics ranks #966 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Quick Ratio compare to AURX and ESLA?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #966 out of 1416 companies for Quick Ratio. This places Actuate Therapeutics in the lower half of its industry. The industry median Quick Ratio is 3.60. Actuate Therapeutics' value of 1.80 is 50% below this benchmark. Historically, Actuate Therapeutics' own Quick Ratio has ranged from 0.03 to 4.71 over the past decade. While the company's 10-year median is 1.05 vs. the industry median of 3.60, Actuate Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actuate Therapeutics's current Quick Ratio of 1.80 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Actuate Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actuate Therapeutics's current Quick Ratio is 1.80, which is 71% above median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Quick Ratio of 1.80. The current Quick Ratio is 1.80, which is 71% above median its 10-year median of 1.05 and 50% below the Biotechnology industry median of 3.60. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Quick Ratio is 1.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score
Get the complete analysis for ACTU
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACTU has been successfully added to your 
